Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Identifieur interne : 000A55 ( Ncbi/Checkpoint ); précédent : 000A54; suivant : 000A56Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Auteurs : Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Monica A. Burke ; Carol Jacques ; Joseph H. FriedmanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Dibenzothiazepines (adverse effects), Dibenzothiazepines (therapeutic use), Drug Tolerance, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (epidemiology), Dyskinesia, Drug-Induced (etiology), Female, Follow-Up Studies, Humans, Levodopa (therapeutic use), Male, Outcome Assessment (Health Care), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Psychotic Disorders (drug therapy), Psychotic Disorders (epidemiology), Psychotic Disorders (etiology), Retrospective Studies, Severity of Illness Index.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Dibenzothiazepines.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- diagnosis : Dyskinesia, Drug-Induced.
- drug therapy : Parkinson Disease, Psychotic Disorders.
- epidemiology : Dyskinesia, Drug-Induced, Psychotic Disorders.
- etiology : Dyskinesia, Drug-Induced, Psychotic Disorders.
- psychology : Parkinson Disease.
- Aged, Drug Tolerance, Female, Follow-Up Studies, Humans, Male, Outcome Assessment (Health Care), Retrospective Studies, Severity of Illness Index.
Abstract
To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).
DOI: 10.1002/mds.10374
PubMed: 12722164
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003796
- to stream PubMed, to step Curation: 003796
- to stream PubMed, to step Checkpoint: 003740
- to stream Ncbi, to step Merge: 000A55
- to stream Ncbi, to step Curation: 000A55
Links to Exploration step
pubmed:12722164Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA. Hubert-Fernandez@mhri.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></author><author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A" last="Burke">Monica A. Burke</name></author><author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12722164</idno><idno type="pmid">12722164</idno><idno type="doi">10.1002/mds.10374</idno><idno type="wicri:Area/PubMed/Corpus">003796</idno><idno type="wicri:Area/PubMed/Curation">003796</idno><idno type="wicri:Area/PubMed/Checkpoint">003740</idno><idno type="wicri:Area/Ncbi/Merge">000A55</idno><idno type="wicri:Area/Ncbi/Curation">000A55</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA. Hubert-Fernandez@mhri.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></author><author><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A" last="Burke">Monica A. Burke</name></author><author><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Dibenzothiazepines (adverse effects)</term><term>Dibenzothiazepines (therapeutic use)</term><term>Drug Tolerance</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (epidemiology)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (epidemiology)</term><term>Psychotic Disorders (etiology)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Tolerance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Outcome Assessment (Health Care)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Rhode Island</li></region></list><tree><noCountry><name sortKey="Burke, Monica A" sort="Burke, Monica A" uniqKey="Burke M" first="Monica A" last="Burke">Monica A. Burke</name><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name><name sortKey="Jacques, Carol" sort="Jacques, Carol" uniqKey="Jacques C" first="Carol" last="Jacques">Carol Jacques</name><name sortKey="Trieschmann, Martha E" sort="Trieschmann, Martha E" uniqKey="Trieschmann M" first="Martha E" last="Trieschmann">Martha E. Trieschmann</name></noCountry><country name="États-Unis"><region name="Rhode Island"><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000A55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:12722164
|texte= Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:12722164" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |